Paclitaxel

Paclib®

Prescription Drug

Indication

Ovarian Cancer

• First-line treatment of advanced ovarian cancer in combination with cisplatin
• Subsequent treatment of advanced ovarian cancer

Breast cancer

• Adjuvant treatment of node positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy
• Treatment of breast cancer after the failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated
• For the initial treatment of locally advanced or metastatic breast cancer
  • In combination with an athracycline in patients for whom anthracycline therapy is suitable, OR
  • In combination with trastuzumab, in patients who over-express human epidermal growth factor receptor 2 (HER-2) at a 3+ level as determined by immunohistochemistry and for whom anthracycline is not suitable

Advanced Non-small Cell Lung Cancer (NSCLC)

• First-line treatment, in combination with cisplatin, of patients with NSCLC who are not candidates for surgery and/or radiation therapy

AIDS-related Kaposi’s Sarcoma

• Palliative treatment of advanced or refractory AIDS-related Kaposi’s sarcoma in patients who have failed prior liposomal anthracycline therapy

Dosage and Administration

For more information on safety, precaution and other information about this product, please see the Product Insert.